GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.
|
Synonyms: A-167 | Cotelet® | HBM-9167 | KL-A167 | KLA167
tagitanlimab is an approved drug
Compound class:
Antibody
Comment: Tagitanlimab (KL-A167) is a humanized anti-programmed cell death-ligand 1 (PD-L1) monoclonal antibody [1]. It is designed to block the inhibitory PD-1/PD-L1 immune checkpoint and restore anti-tumour immunity.
|
Classification ![]() |
|
| Compound class | Antibody |
| Ligand families/groups | Immune checkpoint modulators |
| Approved drug? | Yes. China NMPA (2024) |
International Nonproprietary Names ![]() |
|
| INN number | INN |
| 11843 | tagitanlimab |
Synonyms ![]() |
| A-167 | Cotelet® | HBM-9167 | KL-A167 | KLA167 |
Database Links ![]() |
|
| Specialist databases | |
| IMGT/mAb-DB | 1206 |
| Other databases | |
| GtoPdb PubChem SID | 507750428 |
| Search PubMed clinical trials | tagitanlimab |
| Search PubMed titles | tagitanlimab |
| Search PubMed titles/abstracts | tagitanlimab |